Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company is planning to invest $140m to expand insulin manufacturing facility in Indianapolis, US.
Subscribe to our email newsletter
The 80,000ft² expansion will facilitate insulin cartridge manufacturing for people with diabetes and will help meet the diabetes demand in the country.
Lilly chairman, president and chief executive officer John Lechleiter said that the decision to expand the Indianapolis facility was driven by the firm’s commitment towards addressing long-term needs of Americans suffering from diabetes.
"Lilly is committed to providing a full range of innovative treatment options for people with diabetes," Lechleiter addded.
"The need in our country is great — and it is growing. This investment will help us to better meet that need while expanding our advanced manufacturing footprint in our home state — helping to strengthen Indiana’s bioscience industry."
With plans underway to commence the construction immediately, Eli Lilly expects to complete the project by March 2014 and make it operational in 2015.
Eli Lilly anticipates a requirement of more than 100 skilled, specialized technicians, scientists and engineers to manage the operations once they commence.